|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
|
TWI312285B
(en)
*
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
|
US9533938B2
(en)
|
2007-01-31 |
2017-01-03 |
Biosuccess Biotech Co., Ltd. |
Compositions and methods of use of phorbol esters for the treatment of stroke
|
|
AU2007346591A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
|
MX2011001384A
(es)
|
2008-08-06 |
2011-09-27 |
Gosforth Ct Holdings Pty Ltd |
Composiciones y metodos para tratar trastornos psiquiatricos.
|
|
ES2865504T3
(es)
|
2008-10-16 |
2021-10-15 |
Univ Johns Hopkins |
Procedimientos y composiciones para la mejora de la función cognitiva
|
|
US20120095048A1
(en)
*
|
2009-02-20 |
2012-04-19 |
Region Midt Jylland |
Allosteric binding compounds
|
|
ES2758554T3
(es)
|
2009-12-08 |
2020-05-05 |
Univ Case Western Reserve |
Aminoácidos gama para tratamiento de trastornos oculares
|
|
WO2011143721A1
(en)
*
|
2010-05-21 |
2011-11-24 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating neurodegenerative disorders
|
|
US8609849B1
(en)
|
2010-11-30 |
2013-12-17 |
Fox Chase Chemical Diversity Center, Inc. |
Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
|
|
EP2672822A4
(en)
*
|
2011-02-09 |
2014-08-27 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
|
|
US9682073B2
(en)
|
2011-05-19 |
2017-06-20 |
Gilrose Pharmaceuticals, Llc |
Pre-frontal cortex processing disorder gait and limb impairments treatment
|
|
US20140163070A1
(en)
|
2012-05-17 |
2014-06-12 |
Bruce Roseman |
Treatment for cerebral palsy impaired speech in children
|
|
US8883815B2
(en)
|
2011-05-19 |
2014-11-11 |
Gilrose Pharmaceuticals, Llc |
Treatment for cerebral palsy impaired speech in children
|
|
US10085414B2
(en)
|
2011-05-19 |
2018-10-02 |
Gilrose Pharmaceuticals, Llc |
Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
|
|
US9040082B2
(en)
|
2011-06-24 |
2015-05-26 |
K-Pax Pharmaceuticals, Inc. |
Compositions and methods for treatment of chronic fatigue
|
|
GB201111712D0
(en)
*
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
RU2480214C1
(ru)
*
|
2011-09-22 |
2013-04-27 |
Валентина Ивановна Ахапкина |
Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
|
|
NZ727304A
(en)
*
|
2012-01-18 |
2018-08-31 |
Biosuccess Biotech Co Ltd |
Compositions and methods of use of phorbol esters for the treatment of stroke
|
|
EP2806867A4
(en)
*
|
2012-01-27 |
2015-09-02 |
Catalyst Pharmaceutical Partners Inc |
METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
|
|
EP2829270B1
(en)
|
2012-03-23 |
2020-11-11 |
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China |
Joint product containing synephrine and topiramate
|
|
CN103316026B
(zh)
|
2012-03-23 |
2016-05-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
含芬特明和托吡酯的联合产品及其制备方法
|
|
TW201408294A
(zh)
*
|
2012-07-05 |
2014-03-01 |
Merz Pharma Gmbh & Co Kgaa |
(r)-苯基披喇瑟盪於治療帕金森氏症之用除
|
|
ES2691092T3
(es)
|
2012-08-21 |
2018-11-23 |
Janssen Pharmaceutica Nv |
Anticuerpos contra la risperidona y uso de los mismos
|
|
WO2014031656A1
(en)
|
2012-08-21 |
2014-02-27 |
Ortho-Clinical Diagnostics, Inc |
Antibodies to olanzapine haptens and use thereof
|
|
PL2888592T3
(pl)
|
2012-08-21 |
2018-03-30 |
Janssen Pharmaceutica Nv |
Przeciwciała względem kwetiapiny i ich zastosowania
|
|
JP6131414B2
(ja)
|
2012-08-21 |
2017-05-24 |
ヤンセン ファーマシューティカ エヌ．ベー． |
アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用
|
|
CA2882562C
(en)
|
2012-08-21 |
2019-08-27 |
Eric Hryhorenko |
Antibodies to aripiprazole and use thereof
|
|
JP6450314B2
(ja)
|
2012-08-21 |
2019-01-09 |
ヤンセン ファーマシューティカ エヌ．ベー． |
クエチアピンハプテンに対する抗体及びその使用
|
|
CA2882596C
(en)
|
2012-08-21 |
2019-05-14 |
Ortho-Clinical Diagnostics, Inc. |
Antibodies to olanzapine and use thereof
|
|
EP2888284B1
(en)
*
|
2012-08-21 |
2022-07-06 |
Janssen Pharmaceutica NV |
Antibodies to risperidone haptens and use thereof
|
|
JP2015529199A
(ja)
|
2012-08-21 |
2015-10-05 |
オルソ−クリニカル ダイアグノスティクス，インコーポレイティド |
パリペリドンハプテンに対する抗体及びその使用
|
|
JP2015527365A
(ja)
|
2012-08-21 |
2015-09-17 |
オルソ−クリニカル ダイアグノスティクス，インコーポレイティド |
パリペリドンに対する抗体及びその使用
|
|
JP6389176B2
(ja)
|
2012-08-21 |
2018-09-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
アリピプラゾールハプテンに対する抗体及びその使用
|
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
|
US9265458B2
(en)
|
2012-12-04 |
2016-02-23 |
Sync-Think, Inc. |
Application of smooth pursuit cognitive testing paradigms to clinical drug development
|
|
US9380976B2
(en)
|
2013-03-11 |
2016-07-05 |
Sync-Think, Inc. |
Optical neuroinformatics
|
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
|
JP6433482B2
(ja)
|
2013-03-15 |
2018-12-05 |
エージンバイオ， インコーポレイテッド |
認知機能を改善するための方法および組成物
|
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
|
WO2014144663A1
(en)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
|
BR112015023116A2
(pt)
|
2013-03-15 |
2017-07-18 |
Melior Discovery Inc |
composto, composição, formulação para administração oral, método de tratamento de um distúrbio, e, uso de um composto
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
EP2875810A1
(en)
*
|
2013-11-20 |
2015-05-27 |
Biocodex |
Pharmacological treatment of obsessive-compulsive disorder using Stiripentol or a similar compound
|
|
EP2886116A1
(en)
*
|
2013-12-18 |
2015-06-24 |
Biocodex |
Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
|
|
CA2932301A1
(en)
*
|
2013-12-25 |
2015-07-02 |
Fujimoto Co., Ltd. |
Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder
|
|
WO2015153263A1
(en)
*
|
2014-04-02 |
2015-10-08 |
Yale University |
Compositions and methods to treat addiction
|
|
EP3160445B1
(en)
|
2014-06-26 |
2021-10-20 |
Island Breeze Systems Ca, LLC |
Mdi related products and methods of use
|
|
GB201416017D0
(en)
*
|
2014-09-10 |
2014-10-22 |
New Royal Holloway & Bedford |
An Anticonvulsant Compound
|
|
CN107111673B
(zh)
*
|
2014-09-29 |
2021-03-23 |
周格尼克斯国际有限公司 |
控制药物分配的控制系统
|
|
CN107206093A
(zh)
*
|
2015-01-28 |
2017-09-26 |
韩国真耐瑞斯有限公司 |
用于治疗神经精神类障碍的组合物及方法
|
|
WO2016191288A1
(en)
|
2015-05-22 |
2016-12-01 |
Agenebio, Inc. |
Extended release pharmaceutical compositions of levetiracetam
|
|
EP3319603B1
(en)
*
|
2015-07-08 |
2021-11-17 |
Gilrose Pharmaceuticals, LLC |
Use of methylphenidate for the treatment of gait and limb impairment secondary to pre-frontal cortex processing disorder
|
|
CN106361734A
(zh)
*
|
2015-07-25 |
2017-02-01 |
云南帕精生物科技有限公司 |
一类治疗精神分裂症药物
|
|
JP6983161B2
(ja)
*
|
2015-09-15 |
2021-12-17 |
プラクシス・バイオリサーチ・エルエルシー |
フェンカンファミンのプロドラッグ
|
|
CN106562945A
(zh)
*
|
2015-10-11 |
2017-04-19 |
云南帕精生物科技有限公司 |
一类治疗帕金森病药物
|
|
CA3008048C
(en)
*
|
2015-12-11 |
2023-11-14 |
Aarhus Universitet |
Rufinamide for use in the treatment of myotonia
|
|
EP3390449A1
(en)
|
2015-12-17 |
2018-10-24 |
Janssen Pharmaceutica N.V. |
Antibodies to risperidone and use thereof
|
|
US10435478B2
(en)
|
2015-12-17 |
2019-10-08 |
Janssen Pharmaceutica Nv |
Antibodies to quetiapine and use thereof
|
|
WO2017112701A1
(en)
|
2015-12-22 |
2017-06-29 |
Zogenix International Limited |
Metabolism resistant fenfluramine analogs and methods of using the same
|
|
ES3024232T3
(en)
|
2015-12-22 |
2025-06-04 |
Zogenix International Ltd |
Fenfluramine compositions and methods of preparing the same
|
|
CN105456214A
(zh)
*
|
2015-12-30 |
2016-04-06 |
蔡惠文 |
甲磺酸沙芬酰胺片
|
|
EP3455203B1
(en)
*
|
2016-05-12 |
2021-09-22 |
Research Triangle Institute |
Vinylogous phenethylamines as neurotransmitter releasers
|
|
SG11201900975XA
(en)
|
2016-08-24 |
2019-03-28 |
Zogenix International Ltd |
Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
|
|
JP2020519594A
(ja)
*
|
2017-05-09 |
2020-07-02 |
ゾゲニクス インターナショナル リミテッド |
フェンフルラミンを用いるドゥーゼ症候群の治療方法
|
|
WO2019026019A1
(en)
*
|
2017-08-03 |
2019-02-07 |
Therapeutic Adjuncts Inc. |
USE OF 3-METHYLMETHCATHINONE
|
|
US10682317B2
(en)
|
2017-09-26 |
2020-06-16 |
Zogenix International Limited |
Ketogenic diet compatible fenfluramine formulation
|
|
US12459965B2
(en)
|
2017-10-09 |
2025-11-04 |
Compass Pathfinder Limited |
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
EP4230197A3
(en)
*
|
2017-10-23 |
2024-01-24 |
Cerebral Therapeutics LLC |
High concentration medicant solutions for treating neurological disorders
|
|
CA3081199A1
(en)
*
|
2017-11-14 |
2019-05-23 |
Osaka University |
Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program
|
|
WO2019216919A1
(en)
|
2018-05-11 |
2019-11-14 |
Zogenix International Limited |
Compositions and methods for treating seizure-induced sudden death
|
|
EA202191079A1
(ru)
|
2018-11-19 |
2021-09-20 |
Зодженикс Интернэшнл Лимитед |
Способы лечения синдрома ретта с применением фенфлурамина
|
|
US12377112B2
(en)
|
2019-04-17 |
2025-08-05 |
Compass Pathfinder Limited |
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
|
|
WO2020214960A1
(en)
*
|
2019-04-18 |
2020-10-22 |
Prevep Llc |
Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use
|
|
US12491200B2
(en)
|
2019-05-23 |
2025-12-09 |
Igc Pharma Ip, Llc |
Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome
|
|
HRP20231735T1
(hr)
|
2019-08-26 |
2024-03-15 |
Period Pill Bv |
Liječenje simptoma izazvanih menstrualnim ciklusom
|
|
US12014835B2
(en)
*
|
2020-02-19 |
2024-06-18 |
Vanderbilt University |
Methods for evaluating therapeutic benefit of combination therapies
|
|
RU2743876C1
(ru)
*
|
2020-05-19 |
2021-03-01 |
Татьяна Евгеньевна Ефремова |
Способ реабилитации детей и подростков с поведенческими и эмоциональными нарушениями, страдающих психическими расстройствами
|
|
US11612574B2
(en)
|
2020-07-17 |
2023-03-28 |
Zogenix International Limited |
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
|
AU2021397628A1
(en)
*
|
2020-12-09 |
2023-07-20 |
Eysz, Inc. |
Systems and methods for monitoring and managing neurological diseases and conditions
|
|
GB202101462D0
(en)
*
|
2021-02-03 |
2021-03-17 |
Sanchez Hector Mario |
Combination therapy for treating executive function disorders
|
|
WO2022217066A1
(en)
*
|
2021-04-09 |
2022-10-13 |
The Johns Hopkins University |
Treatment methods and compositions comprising perampanel
|
|
US20220354822A1
(en)
*
|
2021-05-05 |
2022-11-10 |
Mind Medicine, Inc. |
Mdma enantiomers
|
|
US12518388B2
(en)
|
2021-05-28 |
2026-01-06 |
Blinktbi, Inc. |
Systems and methods for eyelid localization
|
|
WO2022265534A1
(ru)
*
|
2021-06-18 |
2022-12-22 |
Гиви Иванович ИКАЕВ |
Способ коррекции психического состояния больного шизофренией
|
|
JP2024524605A
(ja)
*
|
2021-07-08 |
2024-07-05 |
エヌエルエス、ファーマシューティクス、アクチエンゲゼルシャフト |
クライネ－レヴィン症候群の治療における使用のためのベネジン、ピペリジン，２－ベンズヒドリル－３－ヒドロキシ－ｎ－メチル－，塩酸塩およびその誘導体
|
|
WO2023092044A2
(en)
|
2021-11-17 |
2023-05-25 |
Terran Biosciences, Inc. |
Phenethylamine compounds salts, polymorphic forms and methods of use thereof
|
|
CA3239514A1
(en)
*
|
2021-12-09 |
2023-06-15 |
Matthew J. Baggott |
Specialized combinations for mental disorders or mental enhancement
|
|
US20250375129A1
(en)
*
|
2022-02-11 |
2025-12-11 |
Blinktbi, Inc. |
Use of blink reflex for attention-deficit/hyperactivity disorder (adhd) response monitoring and/or treatment selection
|
|
EP4611738A1
(en)
*
|
2022-12-05 |
2025-09-10 |
Lykos Therapeutics, Inc. |
Compositions comprising mdma and methods of using same
|
|
CN116831580B
(zh)
*
|
2023-08-31 |
2023-12-01 |
北京中科心研科技有限公司 |
识别抑郁情绪障碍的计算设备应用、装置及可穿戴设备
|
|
US20250182612A1
(en)
*
|
2023-11-30 |
2025-06-05 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Systems and methods for providing assistance to hearing-impaired pedestrians
|
|
US12475781B2
(en)
|
2023-12-08 |
2025-11-18 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Systems and methods for detecting impaired decision-making pedestrians
|
|
WO2025196662A1
(en)
|
2024-03-20 |
2025-09-25 |
Clearmind Labs Corp. |
Compositions and methods for treating eating disorders
|
|
US12605388B2
(en)
|
2024-09-25 |
2026-04-21 |
Azurity Pharmaceuticals Ireland Limited |
Lamotrigine salts, co-crystals, and compositions
|